ARS Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US82835W1080

SecuritySPRY / ARS Pharmaceuticals, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership3,644,966 shares
Latest Disclosed Value $ 29,269,077
State Street Corp reports 13.07% increase in ownership of SPRY / ARS Pharmaceuticals, Inc.

On May 15, 2026 - State Street Corp filed a 13F-HR form disclosing ownership of 3,644,966 shares of ARS Pharmaceuticals, Inc. (US:SPRY) valued at $29,269,077 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 3,223,581 shares of ARS Pharmaceuticals, Inc.. This represents a change in shares of 13.07% during the quarter. The current value of the position is $33,078,066 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ARS PHARMACEUTICALS COM 82835W108 3,644,966 421,385 13.07 29,269 -22.06 0.0010
2026-02-13 2025-12-31 13F ARS PHARMACEUTICALS COM 82835W108 3,223,581 328,325 11.34 37,555 29.06 0.0013
2025-11-14 2025-09-30 13F ARS PHARMACEUTICALS COM 82835W108 2,895,256 700,763 31.93 29,097 -24.01 0.0010
2025-08-14 2025-06-30 13F ARS PHARMACEUTICALS COM 82835W108 2,194,493 163,259 8.04 38,294 49.86 0.0014
2025-05-15 2025-03-31 13F ARS PHARMACEUTICALS COM 82835W108 2,031,234 -718,667 -26.13 25,553 -11.92 0.0011
2025-02-14 2024-12-31 13F ARS PHARMACEUTICALS COM 82835W108 2,749,901 700,359 34.17 29,011 -2.38 0.0011
2024-11-14 2024-09-30 13F ARS PHARMACEUTICALS COM 82835W108 2,049,542 193,321 10.41 29,718 88.14 0.0012
2024-08-14 2024-06-30 13F ARS PHARMACEUTICALS COM 82835W108 1,856,221 251,671 15.68 15,796 -3.67 0.0007
2024-05-15 2024-03-31 13F ARS PHARMACEUTICALS COM 82835W108 1,604,550 1,027,570 178.09 16,399 418.76 0.0007
2024-02-14 2023-12-31 13F ARS PHARMACEUTICALS COM 82835W108 576,980 40,820 7.61 3,162 56.02 0.0002
2023-11-14 2023-09-30 13F ARS PHARMACEUTICALS COM 82835W108 536,160 97,609 22.26 2,027 -31.04 0.0001
2023-08-14 2023-06-30 13F ARS PHARMACEUTICALS COM 82835W108 438,551 309,360 239.46 2,938 249.35 0.0002
2023-05-15 2023-03-31 13F ARS PHARMACEUTICALS COM 82835W108 129,191 43,300 50.41 841 14.89 0.0000
2023-05-15 2022-12-31 13F/A-99 ARS PHARMACEUTICALS COM 82835W108 85,891 18,300 27.07 733 105.04 0.0000
2023-05-15 2022-12-31 13F ARS PHARMACEUTICALS COM 82835W108 85,891 18,300 733 0.0000
2022-11-15 2022-09-30 13F SILVERBACK THERAPEUTICS COM 82835W108 67,591 0 0.00 357 24.39 0.0000
2022-08-15 2022-06-30 13F SILVERBACK THERAPEUTICS COM 82835W108 67,591 -276,603 -80.36 287 -76.24 0.0000
2022-05-16 2022-03-31 13F SILVERBACK THERAPEUTICS COM 82835W108 344,194 20,181 6.23 1,208 -44.02 0.0001
2022-02-14 2021-12-31 13F SILVERBACK THERAPEUTICS COM 82835W108 324,013 18,944 6.21 2,158 -29.13 0.0001
2021-11-15 2021-09-30 13F SILVERBACK THERAPEUTICS COM 82835W108 305,069 80,750 36.00 3,045 -56.05 0.0002
2021-08-16 2021-06-30 13F SILVERBACK THERAPEUTICS COM 82835W108 224,319 32,155 16.73 6,929 -17.35 0.0004
2021-07-09 2021-03-31 13F/A-1 SILVERBACK THERAPEUTICS COM 82835W108 192,164 192,164 8,384 0.0005
2021-05-17 2021-03-31 13F SILVERBACK THERAPEUTICS COM 82835W108 192,164 192,164 8,384 0.0005
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.